MaximilianKloft

Attending the final #AACR22 Plenary Session on Tumor Evolution and Therapeutic Resistance? Don't miss this @CD_AACR review: Overcoming Resistance to Tumor-Targeted & Immune-Targeted Therapies @mihaela_aldea @FAndreMD @barlesi @jsoriamd @GustaveRoussy aacrjournals.org/cancerdiscover…

#ELCC22 🫁 has been amazing thus far! Great data, educational sessions and #presentations on #LCSM ! Summary #infographic on some new data presented at this amazing @ESMO @IASLC meeting! Cannot wait for #AACR22 #ASCO22 for more progress against #LCSM! @HemOncFellows @OncoAlert

#ESMOVirtualPlenary PEARLS of wisdom by @MartinReck2 where he outlines the ‘elephants’ in the room of periop IO: - key diffs btwn PEARLS & Imp010 - choice btwn neoadj v adj will require multi-d buy-in & change in historic stds - cfDNA may help us tailor periop Tx @myESMO #LCSM

#Multiomics analysis by @RFitzgerald_lab @davidcwedge and colleagues of a longitudinally-sampled cohort of #BarrettsOesophagus patients shows the landscape and timing of alterations during progression to #OesophagealCancer #CancerResearch @NatResCancer go.nature.com/36mjydQ

Prognostic Significance of Negative Lymph Node Long Axis in Esophageal Cancer: Results From the Randomized Controlled UK MRC OE02 Trial journals.lww.com/annalsofsurger…